logo-loader
Hemogenyx Pharmaceuticals PLC

Hemogenyx Pharma Plc - Posting of Annual Report & Notice of AGM

RNS Number : 4119Q
Hemogenyx Pharmaceuticals PLC
05 June 2018
 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

 

Posting of Annual Report

& Notice of Annual General Meeting

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2017 ("2017 Annual Report"), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website:

 

https://www.hemogenyx.com/investors/annual-and-half-year-reports/default.aspx

 

The 2017 Annual Report will be posted to shareholders today.

 

The AGM is to be held on 27 June 2018 at 11am at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London, EC4M 7RD.

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Sir Marc Feldmann, Executive Chairman




Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 




Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar




Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey




Walbrook PR (UK Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893



US Media enquiries


Lowell Goodman

Tel: +1 (323) 646-3249 or  Lowell@corbomitecomms.com

 

 

 



 

About Hemogenyx Pharmaceuticals Plc

 

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFAMRTMBMMBIP
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Hemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it...

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical group raised £3.5 million, which will be utilized to progress its lead product candidate, Chimeric Antigen Receptor T-cells (HEMO-CAR-T), into...

2 weeks, 2 days ago

2 min read